We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of Weight and/or Obesity on Dapsone Drug Concentrations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01165840
Recruitment Status : Completed
First Posted : July 20, 2010
Results First Posted : July 21, 2016
Last Update Posted : July 21, 2016
National Center for Research Resources (NCRR)
Information provided by (Responsible Party):
Ron Hall, Texas Tech University Health Sciences Center

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Obesity
Intervention: Drug: Dapsone

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited into three BMI groups to ensure a wide total body weight distribution, but only one pharmacokinetic model was analyzed with total body weight being one of the potential covariates that was assessed.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Thirty-seven patient provided consent, but only 36 started the study. One patient provided informed consent but was found to have G6PD and was not allowed to continue.

Reporting Groups

Dapsone 100 mg PO x 1 dose

Dapsone: 100 mg PO x 1 dose

Participant Flow:   Overall Study

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

Dapsone 100 mg PO x 1 dose

Dapsone: 100 mg PO x 1 dose

Baseline Measures
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   1 
Between 18 and 65 years   34 
>=65 years   1 
[Units: Years]
Mean (Standard Deviation)
 38.2  (13.7) 
[Units: Participants]
Female   18 
Male   18 
Region of Enrollment 
[Units: Participants]
United States   36 

  Outcome Measures

1.  Primary:   Serum Clearance   [ Time Frame: 72 hours ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Ronald Hall
Organization: Texas Tech University HSC
phone: 214-358-9009
e-mail: ronald.hall@ttuhsc.edu

Responsible Party: Ron Hall, Texas Tech University Health Sciences Center
ClinicalTrials.gov Identifier: NCT01165840     History of Changes
Other Study ID Numbers: AMAIRB97
5UL1RR024982-02 ( U.S. NIH Grant/Contract )
First Submitted: July 16, 2010
First Posted: July 20, 2010
Results First Submitted: October 28, 2015
Results First Posted: July 21, 2016
Last Update Posted: July 21, 2016